{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:44:20Z","timestamp":1793724260156,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ygyno.2022.01.025","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T17:06:19Z","timestamp":1646240779000},"page":"376-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases"],"prefix":"10.1016","volume":"165","author":[{"given":"Amy","family":"Jamieson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Huvila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantale","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoutar","family":"Ennour-Idrissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sebastianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Huntsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Blake","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Grondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.01.025_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990\u20132019","author":"Gu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.025_bb0010","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer","volume":"60","author":"Creasman","year":"1987","journal-title":"Cancer."},{"issue":"9658","key":"10.1016\/j.ygyno.2022.01.025_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Group T writing committee on behalf of the a study. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","year":"2009","journal-title":"Lancet."},{"issue":"23","key":"10.1016\/j.ygyno.2022.01.025_bb0020","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Panici","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.025_bb0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.025_bb0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2017.05.016","article-title":"A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer","volume":"146","author":"Soliman","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.025_bb0035","first-page":"1","article-title":"Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging","author":"Cusimano","year":"2020","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.025_bb0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1470-2045(11)70070-5","article-title":"Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)","volume":"12","author":"Ballester","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.025_bb0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ajog.2016.11.1033","article-title":"Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis","volume":"216","author":"Bodurtha Smith","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.01.025_bb0050","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2022.01.025_bb0055","doi-asserted-by":"crossref","first-page":"836","DOI":"10.5858\/arpa.2015-0220-OA","article-title":"Interobserver variability in the diagnosis of uterine high-grade endometrioid carcinoma","volume":"140","author":"Thomas","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.025_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/annonc\/mdx753","article-title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","volume":"29","author":"de Boer","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.025_bb0065","first-page":"139","article-title":"Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment","volume":"176","author":"Talhouk","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.025_bb0070","first-page":"283","article-title":"Discrepancy of pre- and postoperative grades of patients with endometrial carcinoma","volume":"32","author":"Karateke","year":"2011","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"7447","key":"10.1016\/j.ygyno.2022.01.025_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.025_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.025_bb0085","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.025_bb0090","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.01.025_bb0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"issue":"16","key":"10.1016\/j.ygyno.2022.01.025_bb0100","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.025_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial Cancer: impact on prognosis and benefit from adjuvant therapy","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.025_bb0110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas Deborah","volume":"243","author":"Delair","year":"2018","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.025_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.025_bb0120","first-page":"561","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.025_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ygyno.2014.02.012","article-title":"High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma","volume":"133","author":"Stelloo","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.01.025_bb0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/PGP.0000000000000654","article-title":"Interlaboratory concordance of ProMisE molecular classification of endometrial carcinoma based on endometrial biopsy specimens","volume":"39","author":"Plotkin","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.025_bb0135","author":"Arends"},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.025_bb0140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.025_bb0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.025_bb0150","first-page":"1","article-title":"ESGO \/ ESTRO \/ ESP Guidelines for the management of patients with endometrial carcinoma","author":"Concin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"30","key":"10.1016\/j.ygyno.2022.01.025_bb0155","article-title":"Refining pathologic interpretation of endometrial carcinomas: lessons learned from a nationwide study in a new era of molecular classification","author":"Thompson","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2022.01.025_bb0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.025_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-002256","article-title":"p53abn endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","author":"Jamieson","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.01.025_bb0170","first-page":"1","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2022.01.025_bb0175","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/ijgc-2021-002771","article-title":"High-grade endometrial carcinoma limited to the endometrium or a polyp: is adjuvant treatment necessary?","volume":"31","author":"Dallaire Nantel","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.01.025_bb0180","article-title":"Controversies in the management of early-stage serous endometrial cancer","author":"Alyssa Larish","year":"2021","journal-title":"In Vivo (Brooklyn)"},{"key":"10.1016\/j.ygyno.2022.01.025_bb0185","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-4436","article-title":"Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas","author":"Momeni-Boroujeni","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:01:24Z","timestamp":1758772884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0090825822000646"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}